New Drug Slashes Inflammation Markers 85% in Early Trial — A Statin Moment for Aging?
A new oral drug called BGE-102 is targeting chronic inflammation — a key driver of heart disease, metabolic dysfunction, and brain aging — with striking early results. In a Phase 1 trial, participants with obesity and elevated inflammation saw their high-sensitivity C-reactive protein (hsCRP) drop by around 85% within weeks. IL-6 and fibrinogen, two other cardiovascular risk markers, also fell sharply. The drug works by blocking NLRP3, an inflammasome that acts as a master alarm triggering widespread inflammatory cascades. Taken once daily as a pill, BGE-102 is designed for long-term preventive use — the kind of convenience that makes sustained treatment realistic. While these are early biomarker results, not clinical outcomes, the findings suggest inflammation may finally be approaching the same manageable status that cholesterol reached with statins.